Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-103/CST-107 in Parkinson's Disease with Freezing of Gait
NCT04935762Phase 2Withdrawn
- Sponsor
- CuraSen Therapeutics
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of clenbuterol in Parkinson's disease (PD), sponsored by CuraSen Therapeutics. Planned start Jun 2024; status: withdrawn.
02
Drugs
clenbuterol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04935762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935762.